171 related articles for article (PubMed ID: 11948561)
1. Update on new developments in the study of human teratogens.
Shepard TH; Brent RL; Friedman JM; Jones KL; Miller RK; Moore CA; Polifka JE
Teratology; 2002 Apr; 65(4):153-61. PubMed ID: 11948561
[TBL] [Abstract][Full Text] [Related]
2. Interpretation of recurring weak associations obtained from epidemiologic studies of suspected human teratogens.
Khoury MJ; James LM; Flanders WD; Erickson JD
Teratology; 1992 Jul; 46(1):69-77. PubMed ID: 1641813
[TBL] [Abstract][Full Text] [Related]
3. Big risks in small groups: The difference between epidemiology and counselling.
Friedman JM
Birth Defects Res A Clin Mol Teratol; 2009 Aug; 85(8):720-4. PubMed ID: 19572407
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid in pregnancy: how much are we endangering the embryo and fetus?
Ornoy A
Reprod Toxicol; 2009 Jul; 28(1):1-10. PubMed ID: 19490988
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing surveillance for human teratogenicity: a model approach.
Chambers CD; Braddock SR; Briggs GG; Einarson A; Johnson YR; Miller RK; Polifka JE; Robinson LK; Stepanuk K; Lyons Jones K
Teratology; 2001 Nov; 64(5):252-61. PubMed ID: 11745831
[TBL] [Abstract][Full Text] [Related]
6. Teratogen update: toluene.
Wilkins-Haug L
Teratology; 1997 Feb; 55(2):145-51. PubMed ID: 9143096
[TBL] [Abstract][Full Text] [Related]
7. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
[TBL] [Abstract][Full Text] [Related]
8. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.
van Gelder MM; de Jong-van den Berg LT; Roeleveld N
Hum Reprod; 2014 Jan; 29(1):168-83. PubMed ID: 24108217
[TBL] [Abstract][Full Text] [Related]
9. Human teratogens and evidence-based teratogen risk counseling: the Motherisk approach.
Nava-Ocampo AA; Koren G
Clin Obstet Gynecol; 2007 Mar; 50(1):123-31. PubMed ID: 17304029
[TBL] [Abstract][Full Text] [Related]
10. Congenital abnormalities of 88 children born to mothers who attempted suicide with phenobarbital during pregnany: the use of a disaster epidemiological model for the evaluation of drug teratogenicity.
Timmermann G; Acs N; Bánhidy F; Czeizel AE
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):815-25. PubMed ID: 19551756
[TBL] [Abstract][Full Text] [Related]
11. Selection of controls in case-control studies on maternal medication use and risk of birth defects.
Bakker MK; de Walle HE; Dequito A; van den Berg PB; de Jong-van den Berg LT
Birth Defects Res A Clin Mol Teratol; 2007 Sep; 79(9):652-6. PubMed ID: 17668455
[TBL] [Abstract][Full Text] [Related]
12. [Methods of evaluation of risks tied to drug exposure during pregnancy. Advantages and limits of epidemiology, interpretation of results].
Robert-Gnansia E
Therapie; 2002; 57(2):175-80. PubMed ID: 12185967
[TBL] [Abstract][Full Text] [Related]
13. Bedsharing and maternal smoking in a population-based survey of new mothers.
Lahr MB; Rosenberg KD; Lapidus JA
Pediatrics; 2005 Oct; 116(4):e530-42. PubMed ID: 16199682
[TBL] [Abstract][Full Text] [Related]
14. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors.
Brent RL
Pediatrics; 2004 Apr; 113(4 Suppl):957-68. PubMed ID: 15060188
[TBL] [Abstract][Full Text] [Related]
15. Quantitative analysis of associations between birth defects and suspected human teratogens.
Khoury MJ; James LM; Lynberg MC
Am J Med Genet; 1991 Sep; 40(4):500-5. PubMed ID: 1746618
[TBL] [Abstract][Full Text] [Related]
16. Risk of birth defects associated with nelfinavir exposure during pregnancy.
Covington DL; Conner SD; Doi PA; Swinson J; Daniels EM
Obstet Gynecol; 2004 Jun; 103(6):1181-9. PubMed ID: 15172850
[TBL] [Abstract][Full Text] [Related]
17. Human teratogens: update 2010.
Holmes LB
Birth Defects Res A Clin Mol Teratol; 2011 Jan; 91(1):1-7. PubMed ID: 21254353
[TBL] [Abstract][Full Text] [Related]
18. Gadolinium periconceptional exposure: pregnancy and neonatal outcome.
De Santis M; Straface G; Cavaliere AF; Carducci B; Caruso A
Acta Obstet Gynecol Scand; 2007; 86(1):99-101. PubMed ID: 17230297
[TBL] [Abstract][Full Text] [Related]
19. A review of pregnancy outcomes after exposure to orally inhaled or intranasal budesonide.
Gluck PA; Gluck JC
Curr Med Res Opin; 2005 Jul; 21(7):1075-84. PubMed ID: 16004676
[TBL] [Abstract][Full Text] [Related]
20. [In utero exposure to benzodiazepine. Is there a risk for anal atresia with lorazepam?].
Bonnot O; Vollset SE; Godet PF; d'Amato T; Dalery J; Robert E
Encephale; 2003; 29(6):553-9. PubMed ID: 15029090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
